论文部分内容阅读
目的 探讨重组人干扰素 γ(rhIFN γ)对慢性乙型肝炎肝纤维化患者肝组织病理学变化影响。方法 慢性乙型肝炎肝纤维化患者 4 0例 ,采用rhIFN γ 10 0万U ,肌肉注射 ,疗程为 9个月 ,使用肝纤维化半定量计分方法 ,评价治疗前后肝组织病理学的变化。结果 4 0例患者经rhIFN γ治疗后 ,其肝脏炎症计分由治疗前的 14 .4± 5 .3下降为治疗后的 7.6± 3.6 (P <0 .0 1) ;肝纤维化计分由治疗前的 13.5± 5 .7下降为治疗后的 7.1± 4 .2 (P <0 .0 1) ;血清肝纤维化指标治疗后也明显下降 (P <0 .0 5 )。结论 rhIFN γ对慢性乙型肝炎患者肝脏炎症及纤维化有良好的治疗效果。
Objective To investigate the effect of recombinant human interferon-γ (rhIFNγ) on the pathological changes of liver in chronic hepatitis B patients with liver fibrosis. Methods Forty patients with chronic hepatitis B liver fibrosis were treated with rhIFN γ 10 000 U and injected intramuscularly for 9 months. The changes of liver pathology were evaluated by semi-quantitative method of liver fibrosis. Results After treatment with rhIFN γ, the score of liver inflammation in 40 patients decreased from 14.4 ± 5.3 before treatment to 7.6 ± 3.6 after treatment (P <0.01). The score of liver fibrosis was Before treatment, 13.5 ± 5.7 decreased to 7.1 ± 4.2 (P <0.01) after treatment, and serum hepatic fibrosis index decreased significantly after treatment (P <0.05). Conclusion rhIFN γ has a good therapeutic effect on liver inflammation and fibrosis in patients with chronic hepatitis B.